ArticleNPJ breast cancer2020

The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype.

François Bertucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.